Literature DB >> 31421699

Enkephalins and ACTH in the mammalian nervous system.

Ewing Duque-Díaz1, Olga Alvarez-Ojeda2, Rafael Coveñas3.   

Abstract

The pentapeptides methionine-enkephalin and leucine-enkephalin belong to the opioid family of peptides, and the non-opiate peptide adrenocorticotropin hormone (ACTH) to the melanocortin peptide family. Enkephalins/ACTH are derived from pro-enkephalin, pro-dynorphin or pro-opiomelanocortin precursors and, via opioid and melanocortin receptors, are responsible for many biological activities. Enkephalins exhibit the highest affinity for the δ receptor, followed by the μ and κ receptors, whereas ACTH binds to the five subtypes of melanocortin receptor, and is the only member of the melanocortin family of peptides that binds to the melanocortin-receptor 2 (ACTH receptor). Enkephalins/ACTH and their receptors exhibit a widespread anatomical distribution. Enkephalins are involved in analgesia, angiogenesis, blood pressure, embryonic development, emotional behavior, feeding, hypoxia, limbic system modulation, neuroprotection, peristalsis, and wound repair; as well as in hepatoprotective, motor, neuroendocrine and respiratory mechanisms. ACTH plays a role in acetylcholine release, aggressive behavior, blood pressure, bone maintenance, hyperalgesia, feeding, fever, grooming, learning, lipolysis, memory, nerve injury repair, neuroprotection, sexual behavior, sleep, social behavior, tissue growth and stimulates the synthesis and secretion of glucocorticoids. Enkephalins/ACTH are also involved in many pathologies. Enkephalins are implicated in alcoholism, cancer, colitis, depression, heart failure, Huntington's disease, influenza A virus infection, ischemia, multiple sclerosis, and stress. ACTH plays a role in Addison's disease, alcoholism, cancer, Cushing's disease, dermatitis, encephalitis, epilepsy, Graves' disease, Guillain-Barré syndrome, multiple sclerosis, podocytopathies, and stress. In this review, we provide an updated description of the enkephalinergic and ACTH systems.
© 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adrenocorticotropin hormone; Leucine-enkephalin; Methionine-enkephalin; Opioid; Pro-enkephalin

Mesh:

Substances:

Year:  2019        PMID: 31421699     DOI: 10.1016/bs.vh.2019.05.001

Source DB:  PubMed          Journal:  Vitam Horm        ISSN: 0083-6729            Impact factor:   3.421


  6 in total

Review 1.  Dual Enkephalinase Inhibitors and Their Role in Chronic Pain Management.

Authors:  Warren A Southerland; Justin Gillis; Sumanth Kuppalli; Alex Fonseca; Andrew Mendelson; Storm V Horine; Nitin Bansal; Amitabh Gulati
Journal:  Curr Pain Headache Rep       Date:  2021-03-24

2.  Effects of varying intensities of heat stress on neuropeptide Y and proopiomelanocortin mRNA expression in rats.

Authors:  Nan Zhao; Le Mu; Xiaoyu Chang; Lingqing Zhu; Yao Geng; Guanghua Li
Journal:  Biomed Rep       Date:  2020-08-24

Review 3.  Opioids and Ocular Surface Pathology: A Literature Review of New Treatments Horizons.

Authors:  Celia García-López; Carmen Gómez-Huertas; José-María Sánchez-González; Davide Borroni; Marina Rodríguez-Calvo-de-Mora; Vito Romano; Rahul Rachwani-Anil; Juan-Francisco Ramos-López; Santiago Ortiz-Pérez; Carlos Rocha-de-Lossada
Journal:  J Clin Med       Date:  2022-03-04       Impact factor: 4.241

Review 4.  Endogenous Opioids and Their Role in Stem Cell Biology and Tissue Rescue.

Authors:  Giovannamaria Petrocelli; Luca Pampanella; Provvidenza M Abruzzo; Carlo Ventura; Silvia Canaider; Federica Facchin
Journal:  Int J Mol Sci       Date:  2022-03-30       Impact factor: 5.923

5.  Transcriptional Regulatory Role of NELL2 in Preproenkephalin Gene Expression.

Authors:  Chang Man Ha; Dong Hee Kim; Tae Hwan Lee; Han Rae Kim; Jungil Choi; Yoonju Kim; Dasol Kang; Jeong Woo Park; Sergio R Ojeda; Jin Kwon Jeong; Byung Ju Lee
Journal:  Mol Cells       Date:  2022-07-27       Impact factor: 4.250

Review 6.  Immunomodulatory Role of Neuropeptides in the Cornea.

Authors:  Sudan Puri; Brendan M Kenyon; Pedram Hamrah
Journal:  Biomedicines       Date:  2022-08-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.